Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-09-13
2005-09-13
Desai, Rita (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S542000, C548S544000, C548S578000
Reexamination Certificate
active
06943188
ABSTRACT:
The invention provides compounds of general formula (I) wherein Q, R, R2, R3, R4, R5, R6, R7, and R8are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
REFERENCES:
patent: 3577432 (1971-05-01), Helsley
patent: 3775584 (1973-08-01), Plotnikoff et al.
patent: 4166119 (1979-08-01), Effland et al.
patent: 5576321 (1996-11-01), Krushinski, Jr. et al.
patent: 5614523 (1997-03-01), Audia et al.
patent: 5614533 (1997-03-01), Anderson et al.
patent: 5627196 (1997-05-01), Audia et al.
patent: 5741789 (1998-04-01), Hibschman et al.
patent: 5789402 (1998-08-01), Audia et al.
patent: 2003/0153555 (2002-12-01), Eriksson et al.
patent: 2003/0162772 (2002-12-01), Eriksson
patent: 2003/0144267 (2003-07-01), Hansen et al.
patent: 2003/0158225 (2003-08-01), Hansen et al.
patent: 2004/0110809 (2003-09-01), Brough et al.
patent: 2004/0122020 (2004-06-01), Eriksson et al.
patent: 197 03 131 (1998-07-01), None
patent: 197 55 268 (1999-06-01), None
patent: 0 095 454 (1983-11-01), None
patent: 0 128 007 (1984-12-01), None
patent: 0 496 691 (1992-07-01), None
patent: 0 587 311 (1994-03-01), None
patent: 0 722 941 (1996-07-01), None
patent: 0 903 349 (1999-03-01), None
patent: 2 190 430 (1974-02-01), None
patent: WO 93/25528 (1993-12-01), None
patent: WO 97/23458 (1997-07-01), None
patent: WO 98/32442 (1998-07-01), None
patent: WO 99/25686 (1999-05-01), None
patent: WO 99/31092 (1999-06-01), None
patent: WO 99/65895 (1999-12-01), None
patent: WO 00/35449 (2000-06-01), None
patent: WO 00/35451 (2000-06-01), None
patent: WO 00/53600 (2000-09-01), None
patent: WO 00/58305 (2000-10-01), None
patent: 01/98272 (2001-12-01), None
Christopher J. Cattanach et al., “Indole Series. IV. Tetrahydro-5H-pyrido[4, 3-b]indoles as serotonin antagonists,” J. Chem. Soc. C., vol. 10, p. 1235-1243 (1968).
Marc Payard et al., “N-Aminomethylated Derivatives of Some Hydroxamic Acids as Anti-Inflammatories,” Eur. J. Med. Chem., pp. 1-10 (Jan. 21, 1975).
Archibald et al., “Antiinflammatory 4-acylaminopiperidines”,CAPLUS77:34355 (1972).
Cohen et al., “Cytokine function: A study in biologic diversity”,CAPLUS125:31527 (1996).
Friebe et al., “Piperidinopropyl derivatives and pharmaceutical compositions containing them”,CAPLUS94:103172 (1981).
Leclerc et al., “Derivatives Related to Betaxolol with α-and β-Adrenergic Activities”,Arzneim.-Forsch/Drug. Res.35(11):1357-1367 (1985).
Meurer et al., “Discovery of potent human CCR5 antagonists for the treatment of HIV-1 infection—II.”,CAPLUS2000:331722 (2000).
Rubini et al., “Synthesis of Isosteric Methylene-Oxy Pseudodipeptide Analogues as Novel Amide Bond Surrogate Units”,Tetrahedron42(21):6039-6045 (1986).
Timmermans et al., “Hypotensive Properties of Benzodioxane Derivatives Structurally Related to R 28935. Comparison of Activity with some Receptor Affinities”,Arch. int. Pharmacodyn.255:321-334 (1982).
Tomoaki Komai, et al, “Structure-Activity Relationships of HIV-1 PR Inhibitors Containing AHPBA-II. Modification of Pyrrolidine Ring at P1'Proline,”Bioorganic & Medicinal Chemistry, vol. 4, No. 8, pp. 1365-1933 (1996).
Manabu Hori Kim D. Janda, “A Solube Polymer Approach to the “Fishing Out” Principle: Synthesis and Purification of β-Amino Alchols,” J. Org. Chem, vol. 63, pp. 889-894 (1998).
Jon L. Wright et al., “Discovery of Selective Dopamine D4 Receptor Antagonists: 1-Aryloxy-3-(4-Aryloxypiperidinyl)-2-Propanols”, vol. 7, No. 11, Bioorganic & Medicinal Chemistry Letters, 1377-1380 (1997).
STN International, File CAPLUS, CAPLUS Accession No. 1968.402884.
Frank Navas III, et al., “The Design and Synthesis of a Hapten for 1192U90, A Potential Atypical Antipychotic Agent,” Synthetic Communications, vol. 26, No. 7, pp. 1411-1421 (1996).
O.M. Zack Howard, et al., “Chemokines: progress toward identifying molecular targets for therapeutic agents,” Trends in Biotechnology, vol. 14, pp. 46-51 (1996).
Joseph Hesselgesser, et al., “Identification and Characterization of Small Molecule Functional Antagonists of the CCR1 Chemokine Receptor,” The Journal of Biological Chemistry, vol. 273, No. 25, pp. 15687-15692 (1998).
Christopher J.Cattanach, et al , “Indole Series. IV. Tetrahydro-5H-pyrido[4, 3-b]indoles as serotonin antagonists,” J. Chem. Soc. C., vol. 10, p. 1235-1243 (1968).
Marc Payard, et al., “N-Aminomethylated Derivatives of Some Hydroxamic Acids as Anti-Inflammatories,” Eur. J. Med. Chem., pp. 1-10 (Jan. 21, 1975).
Bodkin Michael
Eriksson Tomas
Hansen Peter
Hemmerling Martin
Henriksson Krister
AstraZeneca AB
Desai Rita
Fish & Richardson P.C.
LandOfFree
Hydroxyalkyl compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hydroxyalkyl compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydroxyalkyl compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3419345